A novel small-molecule antagonizes PRMT5-mediated KLF4 methylation for targeted therapy


Zhou Z., Feng Z., Hu D., Yang P., Gur M., Bahar I., ...Daha Fazla

EBIOMEDICINE, cilt.44, ss.98-111, 2019 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 44
  • Basım Tarihi: 2019
  • Doi Numarası: 10.1016/j.ebiom.2019.05.011
  • Dergi Adı: EBIOMEDICINE
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.98-111
  • İstanbul Teknik Üniversitesi Adresli: Evet

Özet

Background: Triple negative breast cancers (TNBCs) have a poor prognosis and are not amenable to endocrine- or HER2-targeted therapies. The malignant and invasive feature of TNBCs is correlated with its high cancer stem cell population. Recent results from us and others have unveiled an oncogenic role for the PRMT5-KLF4 axis in regulating tumor progression by orchestrating the sternness in mammary tumor cell as well as genome stability. Methylation of KLF4 by PRMT5 leads to KLF4 stabilization, resulting in promoting mitogenesis.